Cost of human immunodeficiency virus infection in Italy, 2007-2009: Effective and expensive, are the new drugs worthwhile?

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 245-252

  Rizzardini, Giuliano ^a   Restelli, Umberto ^b   Bonfanti, Paolo ^c   Porazzi, Emanuele ^b   Ricci, Elena ^a   Foglia, Emanuela ^b   Carenzi, Laura ^a   Croce, Davide ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b CREMS Centre for Research on Health Economics Social and Health Care Management Carlo Cattaneo University LIUC   (Italy)

^c A MANZONI HOSPITAL   (Italy)

Author keywords

Health care costs; Human immunodeficiency virus infection; Retrospective study; Risk factors

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DARUNAVIR; ETRAVIRINE; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AGE; CD4 LYMPHOCYTE COUNT; DRUG COST; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFORMATION PROCESSING; ITALY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OBSERVATIONAL STUDY; OUTPATIENT CARE; PREDICTION; RETROSPECTIVE STUDY; REVIEW;

EID: 84866054720     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: 10.2147/ceor.s35194     Document Type: Review

References (23)

1. Porter K, Babiker A, Bhaskaran K, et al. CASCADE Collaboration. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet. 2003;362:1267-1274.
2. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis. 2006;194:1-5.
3. Salute.org.it. Italian Ministry of Health. Linee Guida Italiane sull'utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1. Ottobre, 2011. http://www.salute.gov.it/imgs/C_17_pubblicazioni_1301_allegato.pdf. Accessed April 10, 2012.
4. EuropeanAIDSClinicalSociety.org. EACS - European AIDS Clinical Society Guidelines. October, 2011. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacsguidelines-v6_english.pdf. Accessed April 10, 2012.
5. AIDSinfo.nih.gov. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 29, 2008. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed April 10, 2012.
6. Sanita.Regione.Lombardia.it. Giunta Regionale Lombardia. Determinazione in ordine alla gestione del servizio socio sanitario regionale per l'esercizio 2012. DRG IX/2633 HYPERLINK "http://www.sanita.regione.lombardia.it/cs/Satellite" www.sanita.regione.lombardia.it/cs/Satellite. Accessed April 10, 2012.
7. Stoll M, Kollan C, Bergmann F, et al. Calculation of direct antiretroviral costs and potential cost savings by using generics in the German HIV ClinSurv Cohort. PlosOne. 2011;6:e23946.
8. ISS:it. Istituto Superiore di Sanità. Aggiornamento delle nuove diagnosi di infezione da HIV e dei casi di AIDS in Italia, http://www.iss.it/binary/pres/cont/dic2008.1228391047.pdf. Accessed April 10, 2012.
9. Rizzardini G, Restelli U, Porazzi E, et al. The cost of HIV disease in Northern Italy: the payer's perspective. J Acquir Immune Defic Syndr. 2011;57:211-217.
10. Drummond FM, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Cary, NC: Oxford University Press; 2005.
11. IMF.org. International Monetary Fund. World Economic Outlook Database, April 2010. http://www.imf.org/external/pubs/ft/weo/2010/01/weodata/weorept.aspx?sy=2000&ey=2010&scsm=1&ssd=1&sort=country&ds=.&br=1&c=136&s=PCPI%2CPCPIPCH%2CPCPIE%2CPCPIEPCH&grp=0&a=&pr1.x=58&pr1.y=14. Accessed April 10, 2012.
12. Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare Expenditures. J Health Econ. 2004;23:525-542.
13. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18:153-171.
14. POSIT. La persona con infezione da HIV in Italia. Rilevazione 2007-2008-2009. HYPERLINK "http://www.posit-nadir.org/posit/ProfiloGenerale.aspx" www.posit-nadir.org/posit/ProfiloGenerale.aspx. Accessed April 10, 2012.
15. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44:990-997.
16. Hill A, Gebo K. Predicting HIV care cost using CD4+ counts from clinical trials. Am J Manag Care. 2007;13:524-528.
17. Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS. 2010;24:2705-2715.
18. Krentz HB, Gill MJ. Cost of medical care for HIV infected patients within a regional population from 1997 to 2006. HIV Med. 2008;9:721-730.
19. Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4+,200 cells/μl) with HIV infection. HIV Med. 2004;5:93-98.
20. Krentz HB, Gill J. Despite CD4+ cell count rebound the higher initial cost of medical care for HIV infected patients persist 5 years after presentation with CD4+ cell counts less than 350 μl. AIDS. 2010;24:2750-2753.
21. Garattini L, Tediosi F, Di Cinto E, et al. Resource utilization and hospital cost of HIV/AIDS care in Italy in the era of highly active antiretroviral therapy. AIDS Care. 2001;13:6733-6741.
22. Cockerham L, Scherzer R, Zolopa A, et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr. 2010;53:102-106.
23. Magoni M, Scarcella C, Vassallo F, et al. The evolving burden of HIV infection compared with other chronic diseases in northern Italy. HIV Med. 2011;12:129-137.